Perit Dial Int
26(2):
207-212
2006
© 2006 International Society for Peritoneal Dialysis
CHANGES IN GLYCATION AND OXIDATION MARKERS IN PATIENTS STARTING PERITONEAL DIALYSIS: A PILOT STUDY
Eric Boulanger1,3,
Olivier Moranne3,
Marie-Paule Wautier1,
Véronique Witko-Sarsat2,
Béatrice Descamps-Latscha2,
Abdelmejid Kandoussi4,
Nicolas Grossin1 and
Jean-Luc Wautier1
Laboratory of Vascular and Cellular
Biology,1 National Institute of
Blood Transfusion; INSERM U507,2
Necker Hospital, Paris; Department of
Nephrology,3 Regional University
Hospital; INSERM U545,4 Pasteur
Institute, Lille, France
Correspondence to: E. Boulanger, Laboratoire de Biologie Vasculaire et
Cellulaire, INTS, 6 Rue A. Cabanel, 75739 Paris Cedex 15,
France.
dreboulanger{at}hotmail.com
- Background: The high incidence of cardiovascular disease in
uremic patients makes it a major cause of morbidity and mortality in those
patients. Uremia is associated with carbonyl and oxidative stress, which
result in the enhanced formation of glycation and oxidation products
respectively. In the present study, the blood levels of advanced glycation end
products (AGEs) and advanced oxidation protein products (AOPPs) were
investigated in uremic patients prior to and after initiation of peritoneal
dialysis (PD).
- Methods: 22 patients [11 nondiabetic (G1) and 11 diabetic (G2)
subjects] were enrolled in a single-center prospective study. Prior to
starting PD (T0) and 6 and 12 months later, changes in AGE and AOPP levels
were analyzed in the total study population and in each group (Friedman test,
intragroup). At each time point, a comparison was made between the levels of
the above-mentioned products in G1 and G2 (Mann-Whitney test, intergroup).
Correlations between AGE or AOPP levels and residual renal function,
peritoneal creatinine clearance, glucose peritoneal equilibration test, or
daily dextrose exposure were analyzed using the Pearson test.
- Results: At T0, no significant difference was found between the
two groups for AGE or AOPP levels. Initiation of PD was followed by an
increase in AGE levels in all patients (p < 0.01 at 6 and 12
months). AGE levels were higher in G2 than in G1 at 12 months after the start
of PD (p < 0.05). In contrast to G2 results, initiation of PD in
G1 led to reduced AOPP levels (at 6 and 12 months, p = 0.01 and
p < 0.05 respectively). However, no correlation between AGE or
AOPP levels and residual renal function, peritoneal creatinine clearance,
glucose peritoneal equilibration test, or daily dextrose exposure could be
established.
- Conclusion: This study demonstrates that PD is associated with
an increase in levels of blood glycation end products, particularly in
diabetic patients, but also with a decrease in oxidative products such as
AOPPs, especially in nondiabetic subjects.
KEY WORDS: Glycation; oxidation; glycoxidation.
Received 17 December 2004;
accepted 11 July 2005.
Copyright © 2006 by Multimed Inc.